Can ensidipine be included in medical insurance in 2025? The latest news is here!

Enasidenib is an oral small molecule inhibitor mainly used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have isocitrate dehydrogenase-2 (IDH2) mutations. The drug helps restore normal cell metabolism pathways by selectively inhibiting IDH2 mutants, thereby promoting the apoptosis of cancer cells and showing good clinical efficacy.

As of April 2025, ensidipine has not been officially launched in the Chinese market and therefore cannot be included in medical insurance. This situation limits access to medicines for many patients in need of this treatment, especially in settings of high financial burden. Because it is not on the market, patients often face a lack of effective treatment options when seeking treatment.

However, with the deepening of global research on the treatment of acute myeloid leukemia, ensidipine has been approved and widely used in other countries and regions, demonstrating its important role in this type of disease. This also provides a favorable support foundation for its future listing in China. Industry insiders generally believe that if ensidipine can enter the domestic market as soon as possible, it will bring new hope to patients with IDH2 mutations and significantly improve their prognosis.

Although ensidipine has not yet been included in medical insurance, new developments may occur in the future as policies change and the market environment evolves. Especially with the accumulation of more clinical data and the gradual in-depth analysis of the cost-benefit of the drug, the medical insurance department may re-examine the inclusion conditions of the drug. If ensidipine begins to be sold in the domestic market and gains certain clinical experience, the possibility of its entry into medical insurance will be greatly increased.

Reference materials:https://www.idhifa.com/